MicroRNA-377 (miR-377) is a predominantly tumor-suppressive microRNA with context-dependent functions in cancer. Located within the imprinted DLK1-DIO3 region on chromosome 14q32, miR-377 regulates proliferation, apoptosis, invasion, metastasis, and treatment response, and its dysregulation contributes to cancer development, progression, and therapy resistance. This review examines the molecular basis of miR-377 silencing, including DNMT1-mediated DNA hypermethylation, EZH2-driven repressive histone modifications, and competing endogenous RNA (ceRNA) mediated post-transcriptional repression. miR-377 exerts convergent effects across multiple oncogenic pathways, including PI3K/AKT, Wnt/β-catenin, TGF-β, NF-κB, and MAPK signaling. Although predominantly tumor-suppressive, context-dependent oncogenic roles have also been reported, particularly in lung, hepatocellular, colorectal, and gastric cancer, underscoring the need for cancer- and isoform-specific interpretation. Circulating miR-377 shows potential as a non-invasive biomarker, though clinical validation remains limited. Preclinical strategies to restore miR-377 function include miRNA mimics, nanoparticle-based delivery, epigenetic reactivation, and CRISPR-based approaches; however, substantial translational barriers remain, and miR-377 restoration warrants further investigation in appropriately defined molecular and clinical settings.
No takes yet. Share an insight, caveat, or question.
Larijani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: